BioSpace News Archive

Incyte (Nasdaq:INCY) is proud to announce the opening call for submissions for its newly launched Incyte Ingenuity Award, an annual program created to support people living with graft-versus-host disease (GVHD), as well as their caregivers and physicians, by encouraging innovative and novel solutions for the challenges currently facing the GVHD community.

ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX) announces the progress of screening PKX-001 for cardiometabolic disorders.

Canon Medical Systems USA, Inc. has received 510(k) clearance for the Aquilion ONE / PRISM Edition, enabling Deep Learning Spectral capabilities that allow for more routine spectral imaging.

RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced that first patient has received injection in the phase 2 trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD) in the United States.

Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies have entered into a definitive agreement for Meridian to acquire Exalenz for ₪6.10 per share in cash with an implied transaction value of approximately $49 million.

Various reports concerning the electrophysiology markets project that the market and its segments will continue to experience substantial growth in the coming years

Toolkit is part of larger initiative, which is reducing reliance on opioids in connection to dental care

Elicio Therapeutics, a next generation immuno-oncology company, today announced Peter DeMuth, PhD., Elicio Vice President of Research, will present “Targeting the Lymph Nodes to Enhance Mutant KRAS-Specific Vaccine Responses,” at the upcoming RAS-Targeted Drug Discovery Summit in Vienna, Austria, from February 25 to 27, 2020.

Worldwide Clinical Trials, Inc. announced that Mike Mencer has joined the company as the EVP and General Manager of Worldwide’s Early Phase Services, focusing on the Bioanalysis Lab in Austin, Texas, and the Clinical Pharmacology Unit clinic in San Antonio, Texas.

LivaNova PLC commends the recent international consensus statement published in the Journal of Affective Disorders for recommendations to identify, assess and manage depression for patients unable to achieve or sustain symptom remission despite serial treatment trials.1 While the diagnosis for these patients is often “Treatment-Resistant Depression”, the authors conclude that “Difficult-to-treat Depression” has semantic and conceptual advantages.